DR. RICARDO DANIEL PARRONDO M.D. NPI 1164818613

NPI Details

DR. Ricardo Daniel Parrondo, M.D. is a hematology and oncology internal medicine in Jacksonville, FL with 10 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Ricardo Daniel Parrondo, M.D. NPI is 1164818613. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4500 SAN PABLO RD S
JACKSONVILLE, FL
ZIP 32224
Phone: (904) 953-2000

The NPI 1164818613 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Telephone or internet assessment with written report by consulting physician, 5 minutes or more (HCPCS:99451)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)

The enumeration date for this NPI number is 4/11/2015 and was last updated on 9/1/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: